Navigation Links
Cambrex Reports First Quarter 2009 Results
Date:5/5/2009

itable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's annual report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com 



                               CAMBREX CORPORATION
                          Statement of Profit and Loss
                 For the Quarters Ended March 31, 2009 and 
'/>"/>
SOURCE  Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related biology technology :

1. Cambrex Receives Notice Regarding NYSE Listing
2. Cambrex Reports Third Quarter 2008 Results
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
5. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
6. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. United Therapeutics Reports First Quarter 2009 Financial Results
9. Osteotech Reports First Quarter 2009 Financial Results
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 ... ancestry tracing for people of African descent, today ... product offering. For people of all races, myDNAmix ... from five distinct populations: Indigenous Americas (Native American), ... India Subcontinent. , Originally launched in ...
(Date:5/23/2013)... St. Louis, Missouri (PRWEB) May 23, 2013 ... design and manufacture of complete thermal systems, recently ... more than 90 years of experience in designing ... most complete selection of products to serve diverse ... lead-time options is featured at the beginning of ...
(Date:5/22/2013)... 22, 2013 Oven Industries announces the ... integrated potentiometers or via a PC through the TTL ... and one half inches square can deliver up to ... switched, low noise solid state relay. Operator safety is ... the communication port and sensor input. Specifications: Input ...
(Date:5/22/2013)... Boston, MA (PRWEB) May 22, 2013 ... to present at last week’s “Data Demonstration Day” on Capitol ... Cambridge Semantics joined EMC, Google, Microsoft and others to showcase ... the proposed Digital Accountability and Transparency Act (DATA Act). , ... Darrell Issa (R-CA) and Sen. Mark ...
Breaking Biology Technology:AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Watlow Introduces Its New Industrial Heater Catalog 2New AC Temperature Controller Announced by Oven Industries 2Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2
... Jan. 26 WellCentive, LLC,today announced that WellCentive ... Information Exchange) as its patient registry and disease,management ... use of WellCentive Registry, more than 1,000 my1HIE ... will be better able to,provide preventive care services ...
... Jan. 26 Sirion Therapeutics, Inc., a privately held ... Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been ... Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... caused by the herpes simplex virus. The FDA has ...
... YORK, Jan. 26 Netsmart Technologies, Inc., a ... health and human services organizations, today announced it ... the New York State Association of Alcoholism and ... company,s comprehensive education, online learning and learning management ...
Cached Biology Technology:my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/22/2013)... CITY, May 22, 2013 U.S. Forest Service scientists ... that, with funding from the TKF Foundation, will examine ... communities and individuals recover from tragedy. , The TKF ... of six projects selected for grant funding. In addition ... sacred spaces in recovery and resiliency, the 3-year, $585,000 ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 19 2011) Bone marrow-derived stem cells (BMDCs) have been ... to different cell populations in a variety of organs under ... aimed at repairing damaged brain tissue or helping to restore ... to the cerebellum at the back of the brain. In ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
... (IRSF) announced today that it is awarding over $1.5M to ... diverse topics from basic science and disease pathology to developing ... the world,s largest private source of funding for biomedical and ... spending of over $26M since 1998. It is the ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
Biology Products: